Is Celldex Therapeutics, Inc. overvalued or undervalued?

As of 9 November 2022, the valuation grade for Celldex Therapeutics, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant negative ratios, including a Price to Book Value of 2.02, an EV to EBITDA of -3.51, and a ROE of -25.44%. In comparison to peers, Celldex's EV to EBITDA ratio is notably worse than Hims & Hers Health, Inc. at 66.5314 and RadNet, Inc. at 26.0674, both of which are also categorized as risky.
The company's recent stock performance shows a mixed picture; while it outperformed the S&P 500 over the past week and month, it has significantly underperformed over the longer term, with a 1-year return of -38.06% compared to the S&P 500's 17.14%. This suggests that despite short-term gains, the overall valuation and long-term outlook for Celldex Therapeutics remain concerning.